Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Jankovic

Showing results (371-380 of 574) with videos related to

Pageof 58
Sort By:
Toxicon : Official Journal of the International Society on Toxinology|November 27, 2012
Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disordersMarkus Naumann, Dirk Dressler, Mark Hallett, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)|December 6, 2016
Deutetrabenazine in Tics Associated with Tourette SyndromeJoseph Jankovic, Joohi Jimenez-Shahed, Cathy Budman, et al.
Nature Reviews. Neurology|April 26, 2020
Parkinson disease and the immune system - associations, mechanisms and therapeuticsEng-King Tan, Yin-Xia Chao, Andrew West, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 5, 2009
The course of depressive symptoms in early Parkinson's diseaseBernard Ravina, Jordan Elm, Richard Camicioli, et al.
CNS & Neurological Disorders Drug Targets|April 10, 2012
Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's diseaseZhen Zhang, Xuping Li, Wen-jie Xie, et al.
Neurology|January 19, 2018
Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled studyWilliam G Ondo, Jerald H Simmons, Muhammad H Shahid, et al.
Parkinsonism & Related Disorders|April 3, 2010
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystoniaDaniel Truong, Matthew Brodsky, Mark Lew, et al.
Autoimmunity|September 17, 2010
Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian AmericansPhilip R Deitiker, Minako Oshima, Joseph Jankovic, et al.
Journal of the Neurological Sciences|December 17, 2003
Clinical gait and balance scale (GABS): validation and utilizationMadhavi Thomas, Joseph Jankovic, Monthaporn Suteerawattananon, et al.
Journal of Neuroimmunology|November 15, 2011
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/BMinako Oshima, Philip R Deitiker, Joseph Jankovic, et al.
Pageof 58

Showing results (371-380 of 574) with videos related to

Sort By:
Pageof 58
Toxicon : Official Journal of the International Society on Toxinology|November 27, 2012
Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disordersMarkus Naumann, Dirk Dressler, Mark Hallett, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)|December 6, 2016
Deutetrabenazine in Tics Associated with Tourette SyndromeJoseph Jankovic, Joohi Jimenez-Shahed, Cathy Budman, et al.
Nature Reviews. Neurology|April 26, 2020
Parkinson disease and the immune system - associations, mechanisms and therapeuticsEng-King Tan, Yin-Xia Chao, Andrew West, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 5, 2009
The course of depressive symptoms in early Parkinson's diseaseBernard Ravina, Jordan Elm, Richard Camicioli, et al.
CNS & Neurological Disorders Drug Targets|April 10, 2012
Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's diseaseZhen Zhang, Xuping Li, Wen-jie Xie, et al.
Neurology|January 19, 2018
Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled studyWilliam G Ondo, Jerald H Simmons, Muhammad H Shahid, et al.
Parkinsonism & Related Disorders|April 3, 2010
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystoniaDaniel Truong, Matthew Brodsky, Mark Lew, et al.
Autoimmunity|September 17, 2010
Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian AmericansPhilip R Deitiker, Minako Oshima, Joseph Jankovic, et al.
Journal of the Neurological Sciences|December 17, 2003
Clinical gait and balance scale (GABS): validation and utilizationMadhavi Thomas, Joseph Jankovic, Monthaporn Suteerawattananon, et al.
Journal of Neuroimmunology|November 15, 2011
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/BMinako Oshima, Philip R Deitiker, Joseph Jankovic, et al.
Pageof 58